Traws Pharma Inc (TRAW)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.00M
Last updated: Nov 17, 2026 at 4:33 PM ET
Traws Pharma Inc (TRAW) Statistics
Traws Pharma (TRAW) has a market cap of $4.00M and an enterprise value of $1.66M. It kept -807.29% of revenue as net income over the last 12 months. Its share count is up 93.28% from a year earlier.
Total Valuation
Enterprise value is 58.51% below the market cap, as cash exceeds debt.
| Market Cap | $4.00M |
|---|---|
| Enterprise Value | $1.66M |
| Latest price (Nov 17, 2026) | $0.24 |
Key Dates
The next earnings report is expected on Apr 13, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Apr 13, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 89.00% over 52 weeks and trades 42.86% below its 50-day average.
| Beta (1Y) | 1.61 |
|---|---|
| 52-Week Change | -89.00% |
| 1-Month Change | -34.87% |
| 3-Month Change | -55.80% |
| 6-Month Change | -84.99% |
| 5-Year Change | -99.66% |
| 10-Year Change | -100.00% |
| Total Return (1Y) | -89.00% |
| Total Return (3Y CAGR) | -75.55% |
| Total Return (5Y CAGR) | -68.65% |
| Max Drawdown (1Y) | -92.20% |
| Max Drawdown (3Y) | -99.13% |
| Sharpe Ratio (1Y) | -1.66 |
| Correlation with SPY (1Y) | 0.17 |
| 50-Day Average | $0.42 |
| 200-Day Average | $1.04 |
| 52-Week Range | $0.22 to $2.98 |
| RSI (14 Days) | 34.4 |
| Average Volume (20 Days) | 199.76K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.52x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 0.52x |
|---|---|
| Quick Ratio | 0.52x |
| Debt / Equity | 0.00x |
Returns and Efficiency
| Return on Assets (ROA) | -281.19% |
|---|---|
| ROA (5Y Average) | -58.70% |
| Asset Turnover | 0.26x |
Scores
TRAW has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue of $2.62M over the last 12 months is down 7.97% from the 12 months before.
| Revenue | $2.62M |
|---|---|
| Revenue Growth (YoY) | -7.97% |
| Gross Profit | $2.62M |
| Operating Income | -$21.09M |
| Pretax Income | -$21.09M |
| Net Income | -$21.15M |
| EBITDA | -$20.91M |
| EBIT | -$21.09M |
| Reported EPS (TTM) | -$1.41 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $2.34M |
|---|---|
| Total Debt | $0 |
| Net Cash | $2.34M |
| Net Cash Per Share | $0.14 |
| Working Capital | -$4.67M |
| Shareholder Equity | -$2.13M |
| Tangible Book Value | -$4.53M |
| Total Assets | $7.52M |
| Total Liabilities | $9.65M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$15.32M |
|---|---|
| FCF Per Share | -$1.16 |
| Depreciation and Amortization | $175.00K |
| Share Repurchases | $2.96M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -805.00%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -805.00% |
| Pretax Margin | -804.85% |
| Net Margin | -807.29% |
| EBITDA Margin | -798.17% |
| EBIT Margin | -804.85% |
| Gross Margin (5Y Average) | 98.94% |
Growth
Revenue grew 131.12% a year over 3 years.
| Revenue Growth (3Y CAGR) | +131.12% |
|---|---|
| Revenue Growth (5Y CAGR) | +64.59% |
Dividends and Yields
TRAW does not pay a dividend.
| Buyback Yield | -30.43% |
|---|---|
| Shareholder Yield | -30.43% |
Stock Splits
The last split was a 1-for-25 reverse split on Sep 23, 2024.
| Last Split Date | Sep 23, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:25 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About TRAW
What is TRAW's market cap?
Traws Pharma has a market cap of $4.00M. Its enterprise value, which adds debt and subtracts cash, is $1.66M.
How many shares of TRAW are outstanding?
Traws Pharma has 17.04M shares outstanding. The count is up 93.28% from a year earlier.
Does TRAW pay a dividend?
No. Traws Pharma does not pay a dividend.
How much debt does TRAW have?
Traws Pharma has $0 of total debt and $2.34M of cash and equivalents, a net cash position of $2.34M.
TRAW pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors